Regeneron’s Global Program Head for Rimbocertamab Discusses Key Findings from Phase I/II Multiple Myeloma Study

In an interview with Pharm Exec deputy editor Don Tracy, Karen Rodriguez-Lorenc, global program head for Linvoseltamab at Regeneron, discusses the top-line results from the ongoing Phase I/II study of Linvoseltamab in multiple myeloma that led to the submission of an FDA Biologics License Application (BLA).